Getting acquainted with Cortical Dynamics’ Management and Organisation Structure

A rising star in the growing medical technology space, Cortical Dynamics Limited has developed a breakthrough MedTech with Global Scaling Potential, the Brain Anaesthesia Response Monitor (BARM), addressing a significant unmet need of a reliable objective measure of consciousness during surgery.

Cortical’s Versatile, Innovative Industry Disruptive Technology

Cortical’s unique system is with an algorithm based physiological principles of operation and is thus patient specific, rather than Cortical’s major competitors BIS & E-Entropy whose technology is based on statistical standards.

The BARM System uniquely produces two measures-Composite Cortical State (CCS), measures the level of consciousness of the patient under anaesthesia; and Cortical Input (CI) -which measures analgesia (pain input received by the brain). These exceptional feature together with other significant competitive advantages distinguishes BARM from its peers BIS from Medtronic and E-Entropy from GE.Cortical’s Significant Achievements Validates BARM’s Success

BARM’s success is authenticated by the substantial patent coverage with 22 registered patents globally, clinical trials and regulatory approvals. Additionally, the Company marked its footprints in the extremely competitive Australian technology space by bagging several awards and accolades during its journey that started in 2004.

Driving Force Behind Cortical- A Strong Management Team

Cortical’s Board and Management consists of an international leadership team holding a proven extensive commercialisation expertise in the sector, both locally and globally. The team is capable of providing benefit what stakeholders entail for their investment. The Company continues to strategically build robust rapport with main distributors to steer product sales supported by a successful Business Model.

Management Team 

Let’s peek into the management team of Cortical streeing its mission.

An experienced corporate finance expert, Mr. David has an extensive expertise in the stock broking industry and capital markets. He also holds a position of Chairman of Grandbridge Ltd and an ASX listed company, BPH Energy Ltd.

He is a member of the Australian Institute of Management; an Associate Member of the Financial Services Institute of Australasia, and a Fellow of the Institute of Company Directors of Australia.
Serving as Cortical’s Chairman from the last 13 years.

Executive Chairman
Mr David Breeze Chairman,
B. Ec, MBA F.A.I.C.D

Prior Work Experience

Mr David holds rich experience in transaction structuring, corporate advisory together with capital raising for more than eighty listed and unlisted companies involving in excess of $250 million, covering a diverse range of sectors including oil and gas, gold, biotechnology and manufacturing. Prior to his current role, Mr David led a distinguished career, serving as executive, consulting and/or board positions across diverse stockbroking companies in Australia.

His work has been published in the Journal of Securities Institute of Australia. Under the Corporations Act, he has also served as an Independent Expert. Mr David’s formerly served as:

  • Corporate consultant to Daiwa Securities
  • Manager of Corporate Services for Eyres Reed McIntosh
  • State Manager and Associate Director for BNZ North’s, a stock broking firm

Mr Gary has over 30 years of Australian and international experience with expertise in marketing & sales. He has expertise in acquiring new international business collaborations with manufacturers in Asia, USA and Europe, looking after supply and distribution of Medical Consumables & Devices. He has also effectively managed high-performance sales teams generating up to $90 million in annual revenues.

Key Responsibilities in Cortical: corporate strategy, sales and marketing management and supply agreements.

Managing Director
Mr Gary Todd
B. Compt.

Prior Work Experience:

While completing his Bachelor of Accounting Science degree, Mr Gary concurrently worked with Deloitte in his first working life role, later transitioning into to sales and marketing, joining Unilever. His work profile includes:

  • Moved to Sydney in 2003 where he served as divisional business manager and sales and marketing manager within the IT&T, medical consumables and devices markets.
  • Emigrated to London from South Africa in 1996, where he worked for Cable & wireless Global Markets, Telewest Communications (now part of Virgin media) and IBM Global Services as a financial analyst adding an international experience to his profile.
  • Three years with Consol Glass in South Africa.
  • Five years’ with Unilever in South Africa
  • Five years with Deloitte in South Africa
One of the founders of Cortical Dynamics, Professor David Liley is also one of Cortical’s Key Personnel. He holds a graduate degree in Medicine (1990) at the University of Auckland, and a PhD in Psychiatry and Applied Mathematics (1996).

Professor Liley is registered as a medical practitioner with Medical Board of Australia. He takes care of design of hospital trial procedures for the BARM and has numerous publications in international peer-reviewed scientific journals, he is also co-authoring multiple book chapters on brain and anaesthesia modelling.

Chief Scientific Officer &
Non-executive Director
Professor David Liley,
MBChB, PhD

Key Responsibilities in Cortical: technical direction, data acquisition oversight  and validation of research. Patent portfolio development, international      research collaboration and product trials.

Professor Liley’s honorary appointments are at:

  • University of Melbourne, Department of Medicine
  • St Vincent’s Hospital Melbourne, Clinical Neurosciences department, and
  • Swinburne University of Technology, Centre for Human Psychopharmacology

Having a focus on commercialisation and start-up companies, Dr Bruce consults Cortical Dynamics on intellectual property matters.

Dr Bruce has served for several company panels as well as government granting bodies including Commercialisation Australia, Clean Technology Investment Committee and the Climate Ready Committee.

Key Responsibilities in Cortical: Acting as Corporate Development Director – Planning, compliance hospital liaison and strategy.

Non-executive Director
Dr Bruce Whan,
PhD

Prior Work Experience:

Dr Bruce has mainly worked at Swinburne University and has extensive experience in the management of innovation and commercialisation of research and development including linking research with industry. He is proactively taking part in spin-off company formation, management and governance.

Mr Delacretaz is one of the founders of Cortical Dynamics.  He has over 30 years’ experience as the managing or technical director for several successful biotechnology, ICT, and electronic manufacturing companies.

Mr Louis has extensive experience in strategic planning and leading operational initiatives and operational management of business development, design and production facilities for globally marketed products.

Chief Technical Officer
Mr Louis Delacretaz,
MBA

Key Responsibilities in Cortical: product development, electronic design & manufacturing including the outsourcing of a package of work to a capable innovative product development resource

Prior Work Experience:

He possesses in-depth experience in dealing with government agencies, international organisations and forming start-up organisations, and Mr Louis has an MBA and is a fellow of the Australian Institute of Company Directors, was a national finalist in the Yellow Pages Business Idea Awards.

Dr Mehrnaz graduated with a PhD degree in Biomedical Engineering from Monash University in 2008.

Her PhD work contributed to the emerging development of Electrovestibulography as a novel diagnostic tool.  Her research includes measurement and processing of physiological signals using conventional and novel recording techniques.
Her work has been published in international peer-reviewed journals.

Key Responsibilities in Cortical: Serving as a Principal Scientist.

Dr Mehrnaz Shoushtarian,
PhD

Cortical’s Advisory Panel

Cortical’s Oragnisational Structure

For marketing related activities, the Company has appointed Reno Wright Smith & Partners to take a step forward in entering the European market for the BARM System technology.  Based in Chicago, Reno Wright Smith & Partners (RWS), have profound and extensive experience across wide range of medical specialists, both in US and Europe. They also hold the expertise in commercialisation for medical technologies that are in early stages.

A strong Management team signifies the backbone of Company’s Success. Cortical’s significant progress in the development of novel BARM system is backed by a strong and efficient management team, that provides guidance and confidence in the company’s ability to recognize and accomplish the development and sales process for this well- defined, novel, proprietary, industry-disruptive medical technology.

Please click here for the offer document.


Disclaimer

This website is a service of Kalkine Media Pty. Ltd. A.C.N. 629 651 672. The website has been prepared for informational purposes only and is not intended to be used as a complete source of information on any particular company. The above article is sponsored but NOT a solicitation or recommendation to buy, sell or hold the stock of the company (or companies) under discussion. We are neither licensed nor qualified to provide investment advice through this platform.

Join Our Discussion

Start discussion with value Investors for ASX Stock Market Investment and Opinion.


6 Cannabis Stocks under Investor’s Limelight…

Cannabis companies that sell both medicinal weed and recreational pot. Marijuana stocks to look at. Marijuana mergers and acquisitions. Dispensary data analytics. Upcoming marijuana IPO’s Those phrases have become increasingly common as marijuana legalization spreads.

Global spending on legal cannabis is expected to grow 230% to $32 billion in 2020 as compared to $9.5 in 2017, according to Arcview Market Research and BDS Analytics. As of June 29, 2018 the United States Marijuana Index, despite a lot of uncertainty around regulations, has over the past 1 year gained 71.49%, as compared to about 12% gain seen by the S&P 500.

Click here for your FREE Report